デフォルト表紙
市場調査レポート
商品コード
1482398

ウイルスベクター製造市場：地域別（北米、欧州、アジア太平洋、ラテンアメリカ、中東アフリカ）：世界の産業分析、規模、シェア、成長、動向、2024-2032年予測

Viral Vector Manufacturing Market by Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

出版日
ページ情報
英文 306 Pages
納期
2～5営業日
カスタマイズ可能
ウイルスベクター製造市場：地域別（北米、欧州、アジア太平洋、ラテンアメリカ、中東アフリカ）：世界の産業分析、規模、シェア、成長、動向、2024-2032年予測
出版日: 2024年05月13日
発行: Persistence Market Research
ページ情報: 英文 306 Pages
納期: 2～5営業日
GIIご利用のメリット

  • 全表示

  • 概要
  • 目次
概要

Persistence Market Research社は、ウイルスベクター製造市場の徹底的な分析を実施し、その世界の状況を詳述した包括的なレポートを提供しています。この詳細な出版物は、市場力学、動向、機会、課題に関する貴重な洞察を提供し、その構造の包括的な概要を提供します。独占データと統計に裏打ちされた本調査は、2024年から2032年までのウイルスベクター製造市場の予想成長軌道を予測しています。

ウイルスベクター製造の世界収益は2024年に6億2,470万米ドルに達し、市場は18.7%のCAGR（複合年間成長率）で成長すると予測されます。2032年には34億6,000万米ドルの評価額に達すると予測されています。

主な洞察

  • ウイルスベクター製造市場規模（2024年）：6億2,470万米ドル
  • 予測市場価値（2032年）：34億6,000万米ドル
  • 世界市場成長率（CAGR 2024-2032）：18.7%.

ウイルスベクター製造市場-レポート範囲：

ウイルスベクターは、遺伝子治療、ワクチン開発、分子生物学研究など様々な分野で極めて重要な役割を果たしています。これらのベクターは、標的細胞に遺伝物質を送達し、治療遺伝子や抗原の発現を促進することができる人工ウイルスです。ウイルスベクター製造市場は、製薬会社、バイオテクノロジー企業、研究機関、製造受託機関（CMO）にサービスを提供しており、アデノ随伴ウイルス（AAV）、レンチウイルス、アデノウイルス、レトロウイルスなど、さまざまなウイルスベクター製造サービスを提供しています。市場成長の原動力となっているのは、幅広い遺伝性疾患、感染症、がんをターゲットとした遺伝子治療やワクチン候補に対する需要の高まりです。さらに、ウイルスベクターの設計、製造技術、規制の枠組みにおける進歩が市場拡大をさらに加速させています。

市場成長の促進要因：

世界のウイルスベクター製造市場は、脊髄性筋萎縮症（SMA）や血友病などの希少遺伝性疾患やがん免疫療法の治療における遺伝子治療の採用増加など、いくつかの要因によって推進されています。製薬会社や学術機関による新規遺伝子治療やワクチン開発のための研究開発（R&D）活動への投資が増加していることが、ウイルスベクター製造サービスの市場需要を牽引しています。さらに、自己不活性化レンチウイルスベクターや次世代AAVベクターなどの革新的なウイルスベクタープラットフォームの出現は、導入効率、安全性、拡張性を高め、市場の成長を促進しています。

市場抑制要因：

有望な成長見通しにもかかわらず、ウイルスベクター製造市場は、製造の拡張性、製品の品質、規制遵守に関する課題に直面しています。細胞培養プロセス、精製技術、品質管理アッセイなど、ウイルスベクター製造の複雑な性質は、製造業者にとって技術的・物流的なハードルとなり、生産収率やタイムラインに影響を及ぼします。さらに、特に遺伝子治療用途において、ウイルスベクターの製造、試験、流通を管理する厳しい規制要件は、市場関係者にコンプライアンス上の負担を課し、運用コストを増加させる。これらの課題に対処するには、製品の一貫性、安全性、規制遵守を確保するために、プロセスの最適化、自動化、分析技術への投資が必要です。

市場機会：

ウイルスベクター製造市場は、技術革新、治療法の進歩、戦略的提携によって大きな成長機会がもたらされます。合成AAVや改変アデノウイルスなどの新規ウイルスベクタープラットフォームの開発により、遺伝子治療やワクチン開発の応用範囲が拡大し、アンメットメディカルニーズへの対応やメーカーの収益源の多様化が進みます。さらに、シングルユース・バイオリアクター、連続製造、遺伝子編集ツールなどの高度な製造技術の統合は、生産効率、柔軟性、費用対効果を高め、ウイルスベクターベースの製品の迅速なスケールアップと商業化を可能にします。戦略的パートナーシップ、ライセンス契約、買収により、技術移転、生産能力拡大、市場浸透が促進され、企業は進化するウイルスベクター製造の展望において長期的な成功を収めることができます。

本レポートで扱う主な質問

  • 世界のウイルスベクター製造市場の成長を促進する主な要因は何か？
  • どのウイルスベクタープラットフォームと治療アプリケーションが、さまざまな業界セグメントで市場需要を牽引しているか？
  • 技術の進歩はウイルスベクター製造市場の競合情勢をどのように変えているのか？
  • ウイルスベクター製造市場に貢献している主要プレイヤーは誰で、市場のリーダーシップを維持するためにどのような戦略を採用しているのか？
  • 世界のウイルスベクター製造市場における新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/分類
  • 市場の定義/範囲/制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • イノベーション/開発動向

第4章 主な内容

  • 製品採用分析
  • 規制シナリオ
  • PESTEL分析
  • ポーターの分析
  • メーカー別の主なプロモーションおよびブランディング戦略
  • バリューチェーン分析

第5章 COVID-19危機分析

  • 2024年の市場シナリオ
  • COVID-19と影響分析
    • ウイルスタイプ別
    • 発現システム別
    • 用途別
    • エンドユーザー別
    • 地域別

第6章 市場背景

  • マクロ経済要因
  • 予測要因-関連性と影響
  • 市場力学

第7章 世界のウイルスベクター製造市場の需要（金額および規模）分析

  • 過去の市場（金額）分析、2019-2023年
  • 現在および将来の市場（金額）予測、2024～2032年

第8章 世界のウイルスベクター製造市場分析：ウイルスタイプ別

  • イントロダクション/主な調査結果
  • 過去の市場規模（金額）分析、2019年～2023年
  • 現在および将来の市場規模（金額）分析・予測、2024-2032年
    • レンチウイルスベクター
    • アデノウイルスベクター
    • アデノ随伴ウイルスベクター（AAV）
    • レトロウイルス
  • ウイルスタイプ別の市場魅力度分析

第9章 世界のウイルスベクター製造市場分析：発現システム別

  • イントロダクション/主な調査結果
  • 過去の市場規模（金額）分析、2019年～2023年
  • 現在および将来の市場規模（金額）分析・予測、2024-2032年
    • 一時的
    • 安定
  • 表現システムによる市場魅力度分析

第10章 世界のウイルスベクター製造市場分析：用途別

  • イントロダクション/主な調査結果
  • 過去の市場規模（金額）分析、2019年～2023年
  • 現在および将来の市場規模（金額）分析・予測、2024-2032年
    • 遺伝子治療
    • ワクチン
    • がん治療
    • その他
  • 用途別の市場魅力度分析

第11章 世界のウイルスベクター製造市場分析：エンドユーザー別

  • イントロダクション
  • 過去の市場規模（金額）分析、2019年～2023年
  • 現在および将来の市場規模（金額）分析・予測、2024-2032年
    • バイオ医薬品企業
    • 学術研究機関
    • 契約研究機関
    • 契約製造組織
  • エンドユーザー別市場魅力度分析

第12章 世界のウイルスベクター製造市場分析：地域別

  • イントロダクション
  • 過去の市場規模（金額）分析、2019年～2023年
  • 現在および将来の市場規模（金額）分析・予測、2024-2032年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 南アジア
    • 東アジア
    • オセアニア
    • 中東・アフリカ
  • 地域別市場魅力度分析

第13章 北米のウイルスベクター製造市場分析

第14章 ラテンアメリカのウイルスベクター製造市場分析

第15章 欧州のウイルスベクター製造市場分析

第16章 南アジアのウイルスベクター製造市場分析

第17章 東アジアのウイルスベクター製造市場分析

第18章 オセアニアのウイルスベクター製造市場分析

第19章 中東およびアフリカのウイルスベクター製造市場分析

第20章 市場構造分析

  • 企業階層別市場分析
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第21章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • Thermo Fisher Scientific Inc
    • Charles River（Cobra Biologics）
    • Novasep
    • uniQure NV
    • Waisman Biomanufacturing
    • Creative Biogene
    • GenScript Biotech Corporation
    • Novartis AG
    • Merck KGaA.
    • Takara Bio Inc.
    • FUJIFILM Diosynth Biotechnologies
    • Lonza
    • Danaher Corp.（Aldevron）
    • Sirion-Biotech GmbH
    • AGC Biologics

第22章 使用される前提条件と頭字語

第23章 調査手法

目次
Product Code: PMRREP26923

Persistence Market Research has conducted a thorough analysis of the Viral Vector Manufacturing Market, providing a comprehensive report detailing its global landscape. This in-depth publication offers valuable insights into the market's dynamics, trends, opportunities, and challenges, providing a comprehensive overview of its structure. Backed by exclusive data and statistics, the research predicts the anticipated growth trajectory of the Viral Vector Manufacturing Market spanning from 2024 to 2032.

The global revenue from viral vector manufacturing hit $624.7 million in 2024, and the market is expected to grow at a compound annual growth rate (CAGR) of 18.7%. By 2032, it's projected to reach a valuation of $3.46 billion.

Key Insights:

  • Viral Vector Manufacturing Market Size (2024): $624.7 million
  • Projected Market Value (2032): $3.46 billion
  • Global Market Growth Rate (CAGR 2024-2032): 18.7%.

Viral Vector Manufacturing Market - Report Scope:

Viral vectors play a pivotal role in various fields, including gene therapy, vaccine development, and molecular biology research. These vectors are engineered viruses that can deliver genetic material into target cells, facilitating the expression of therapeutic genes or antigens. The Viral Vector Manufacturing market serves pharmaceutical companies, biotechnology firms, research institutions, and contract manufacturing organizations (CMOs), offering a range of viral vector production services, including adeno-associated viruses (AAVs), lentiviruses, adenoviruses, and retroviruses. Market growth is fueled by the growing demand for gene therapy and vaccine candidates targeting a wide range of genetic disorders, infectious diseases, and cancers. Additionally, advancements in viral vector design, manufacturing technologies, and regulatory frameworks further accelerate market expansion.

Market Growth Drivers:

The global Viral Vector Manufacturing market is propelled by several factors, including the increasing adoption of gene therapy for the treatment of rare genetic diseases, such as spinal muscular atrophy (SMA) and hemophilia, as well as cancer immunotherapy. The rising investment in research and development (R&D) activities by pharmaceutical companies and academic institutions to develop novel gene therapies and vaccines drives market demand for viral vector manufacturing services. Moreover, the emergence of innovative viral vector platforms, such as self-inactivating lentiviral vectors and next-generation AAV vectors, enhances transduction efficiency, safety, and scalability, fostering market growth.

Market Restraints:

Despite promising growth prospects, the Viral Vector Manufacturing market faces challenges related to manufacturing scalability, product quality, and regulatory compliance. The complex nature of viral vector production, including cell culture processes, purification techniques, and quality control assays, poses technical and logistical hurdles for manufacturers, affecting production yields and timelines. Furthermore, stringent regulatory requirements governing the manufacturing, testing, and distribution of viral vectors, particularly in gene therapy applications, impose compliance burdens and increase operational costs for market players. Addressing these challenges necessitates investments in process optimization, automation, and analytical technologies to ensure product consistency, safety, and regulatory compliance.

Market Opportunities:

The Viral Vector Manufacturing market presents significant growth opportunities driven by technological innovations, therapeutic advancements, and strategic collaborations. The development of novel viral vector platforms, such as synthetic AAVs and modified adenoviruses, expands the application scope of gene therapy and vaccine development, addressing unmet medical needs and diversifying revenue streams for manufacturers. Furthermore, the integration of advanced manufacturing technologies, such as single-use bioreactors, continuous manufacturing, and gene editing tools, enhances production efficiency, flexibility, and cost-effectiveness, enabling rapid scale-up and commercialization of viral vector-based products. Strategic partnerships, licensing agreements, and acquisitions facilitate technology transfer, capacity expansion, and market penetration, positioning companies for long-term success in the evolving Viral Vector Manufacturing landscape.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Viral Vector Manufacturing market globally?
  • Which viral vector platforms and therapeutic applications are driving market demand across different industry segments?
  • How are technological advancements reshaping the competitive landscape of the Viral Vector Manufacturing market?
  • Who are the key players contributing to the Viral Vector Manufacturing market, and what strategies are they employing to maintain market leadership?
  • What are the emerging trends and future prospects in the global Viral Vector Manufacturing market?

Competitive Intelligence and Business Strategy:

Leading players in the global Viral Vector Manufacturing market, including Lonza Group AG, Thermo Fisher Scientific Inc., and Cobra Biologics Ltd., focus on innovation, process optimization, and strategic partnerships to gain a competitive advantage. These companies invest in R&D to develop advanced viral vector production platforms, including suspension cell culture systems, transient transfection technologies, and downstream purification methods, meeting the growing demand for scalable and cost-effective manufacturing solutions. Collaborations with biopharmaceutical companies, academic research centers, and regulatory agencies facilitate technology transfer, process validation, and regulatory approval, expediting market entry and product commercialization. Moreover, emphasis on quality management, compliance with Good Manufacturing Practice (GMP) standards, and continuous improvement initiatives ensures product quality, safety, and regulatory compliance, fostering customer trust and brand reputation in the dynamic Viral Vector Manufacturing landscape.

Key Companies Profiled

  • Thermo Fisher Scientific Inc
  • Charles River
  • (Cobra Biologics)
  • NOVASEP
  • uniQure N.V
  • Waisman Biomanufacturing
  • Creative Biogene
  • GenScript Biotech Corporation
  • Novartis AG
  • Merck KGaA
  • Takara Bio, Inc.
  • FUJIFILM Diosynth Biotechnologies
  • LONZA
  • Danaher Corp. (Aldevron)
  • Sirion Biotech GmbH
  • AGC Biologics

Key Segments of Manufacturing of Viral Vector Industry Research

By Virus Type:

  • Lentiviral Vectors
  • Adenoviral Vectors
  • Adeno-Associated Viral Vectors
  • Retrovirus

By Expression System:

  • Transient
  • Stable

By Application:

  • Gene Therapy
  • Vaccines
  • Cancer Therapy
  • Others

By End User:

  • Biotechnology Companies
  • Pharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Academic and Research Institutes

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Inclusions

  • 4.1. Product Adoption Analysis
  • 4.2. Regulatory Scenario
  • 4.3. PESTEL analysis
  • 4.4. Porter's Analysis
  • 4.5. Key Promotional and Branding Strategies, By Manufacturers
  • 4.6. Value Chain Analysis

5. COVID-19 Crisis Analysis

  • 5.1. 2024 Market Scenario
  • 5.2. COVID-19 and Impact Analysis
    • 5.2.1. By Virus Type
    • 5.2.2. By Expression System
    • 5.2.3. By Application
    • 5.2.4. By End User
    • 5.2.5. By Region

6. Market Background

  • 6.1. Macro-Economic Factors
    • 6.1.1. Global GDP Growth Outlook
    • 6.1.2. Global Healthcare Expenditure Outlook
    • 6.1.3. Gloal Gene Therapy Market Outlook
  • 6.2. Forecast Factors - Relevance & Impact
    • 6.2.1. Increasing drug discovery
    • 6.2.2. Rapid growth in the biotechnology and biopharmaceutical industries
    • 6.2.3. Increasing R&D Research in Genetics and Viral Technology
    • 6.2.4. Increasing Adoption of Gene therapy
    • 6.2.5. Increasing R&D in vaccine development
  • 6.3. Market Dynamics
    • 6.3.1. Drivers
    • 6.3.2. Restraints
    • 6.3.3. Opportunity Analysis

7. Global Viral Vector Manufacturing Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, By Virus Type

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis, By Virus Type, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Virus Type, 2024-2032
    • 8.3.1. Lentiviral Vectors
    • 8.3.2. Adenoviral Vectors
    • 8.3.3. Adeno-associated viral vectors (AAV)
    • 8.3.4. Retrovirus
  • 8.4. Market Attractiveness Analysis By Virus Type

9. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, By Expression System

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis By Expression System, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Expression System, 2024-2032
    • 9.3.1. Transient
    • 9.3.2. Stable
  • 9.4. Market Attractiveness Analysis By Expression System

10. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, By Application

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Mn) Analysis, By Application, 2019-2023
  • 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Application, 2024-2032
    • 10.3.1. Gene Therapy
    • 10.3.2. Vaccines
    • 10.3.3. Cancer Therapy
    • 10.3.4. Others
  • 10.4. Market Attractiveness Analysis By Application

11. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, By End User

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
  • 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2032
    • 11.3.1. Biopharmaceutical Companies
    • 11.3.2. Academic & Research Institutes
    • 11.3.3. Contract Research Organizations
    • 11.3.4. Contract Manufacturing Organizations
  • 11.4. Market Attractiveness Analysis By End User

12. Global Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032, by Region

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
    • 12.3.1. North America
    • 12.3.2. Latin America
    • 12.3.3. Europe
    • 12.3.4. South Asia
    • 12.3.5. East Asia
    • 12.3.6. Oceania
    • 12.3.7. Middle East & Africa
  • 12.4. Market Attractiveness Analysis By Region

13. North America Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 13.3.1. By Country
      • 13.3.1.1. U.S.
      • 13.3.1.2. Canada
    • 13.3.2. By Virus Type
    • 13.3.3. By Expression System
    • 13.3.4. By Application
    • 13.3.5. By End User
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Virus Type
    • 13.4.3. By Expression System
    • 13.4.4. By Application
    • 13.4.5. By End User
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. U.S. Viral Vector Manufacturing Market
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Virus Type
        • 13.8.1.2.2. By Expression System
        • 13.8.1.2.3. By Application
        • 13.8.1.2.4. By End User
    • 13.8.2. Canada Viral Vector Manufacturing Market
    • 13.8.3. Introduction
    • 13.8.4. Market Analysis and Forecast by Market Taxonomy
      • 13.8.4.1. By Virus Type
      • 13.8.4.2. By Expression System
      • 13.8.4.3. By Application
      • 13.8.4.4. By End User

14. Latin America Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 14.3.1. By Country
      • 14.3.1.1. Brazil
      • 14.3.1.2. Mexico
      • 14.3.1.3. Argentina
      • 14.3.1.4. Rest of Latin America
    • 14.3.2. By Virus Type
    • 14.3.3. By Expression System
    • 14.3.4. By Application
    • 14.3.5. By End User
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Virus Type
    • 14.4.3. By Expression System
    • 14.4.4. By Application
    • 14.4.5. By End User
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Brazil Viral Vector Manufacturing Market
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Virus Type
        • 14.8.1.2.2. By Expression System
        • 14.8.1.2.3. By Application
        • 14.8.1.2.4. By End User
    • 14.8.2. Mexico Viral Vector Manufacturing Market
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Virus Type
        • 14.8.2.2.2. By Expression System
        • 14.8.2.2.3. By Application
        • 14.8.2.2.4. By End User
    • 14.8.3. Argentina Viral Vector Manufacturing Market
    • 14.8.4. Introduction
    • 14.8.5. Market Analysis and Forecast by Market Taxonomy
      • 14.8.5.1. By Virus Type
      • 14.8.5.2. By Expression System
      • 14.8.5.3. By Application
      • 14.8.5.4. By End User

15. Europe Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 15.3.1. By Country
      • 15.3.1.1. U.K.
      • 15.3.1.2. Germany
      • 15.3.1.3. Italy
      • 15.3.1.4. France
      • 15.3.1.5. Spain
      • 15.3.1.6. Russia
      • 15.3.1.7. Nordic Countries
      • 15.3.1.8. BENELUX
      • 15.3.1.9. Rest of Europe
    • 15.3.2. By Virus Type
    • 15.3.3. By Expression System
    • 15.3.4. By Application
    • 15.3.5. By End User
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Virus Type
    • 15.4.3. By Expression System
    • 15.4.4. By Application
    • 15.4.5. By End User
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. U.K. Viral Vector Manufacturing Market
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Virus Type
        • 15.8.1.2.2. By Expression System
        • 15.8.1.2.3. By Application
        • 15.8.1.2.4. By End User
    • 15.8.2. Germany Viral Vector Manufacturing Market
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Virus Type
        • 15.8.2.2.2. By Expression System
        • 15.8.2.2.3. By Application
        • 15.8.2.2.4. By End User
    • 15.8.3. Italy Viral Vector Manufacturing Market
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Virus Type
        • 15.8.3.2.2. By Expression System
        • 15.8.3.2.3. By Application
        • 15.8.3.2.4. By End User
    • 15.8.4. France Viral Vector Manufacturing Market
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Virus Type
        • 15.8.4.2.2. By Expression System
        • 15.8.4.2.3. By Application
        • 15.8.4.2.4. By End User
    • 15.8.5. Spain Viral Vector Manufacturing Market
      • 15.8.5.1. Introduction
      • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.5.2.1. By Virus Type
        • 15.8.5.2.2. By Expression System
        • 15.8.5.2.3. By Application
        • 15.8.5.2.4. By End User
    • 15.8.6. Russia Viral Vector Manufacturing Market
      • 15.8.6.1. Introduction
      • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.6.2.1. By Virus Type
        • 15.8.6.2.2. By Expression System
        • 15.8.6.2.3. By Application
        • 15.8.6.2.4. By End User
    • 15.8.7. Nordic Countries Viral Vector Manufacturing Market
      • 15.8.7.1. Introduction
      • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.7.2.1. By Virus Type
        • 15.8.7.2.2. By Expression System
        • 15.8.7.2.3. By Application
        • 15.8.7.2.4. By End User
    • 15.8.8. BENELUX Viral Vector Manufacturing Market
      • 15.8.8.1. Introduction
      • 15.8.8.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.8.2.1. By Virus Type
        • 15.8.8.2.2. By Expression System
        • 15.8.8.2.3. By Application
        • 15.8.8.2.4. By End User

16. South Asia Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Indonesia
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Philippines
      • 16.3.1.5. Thailand
      • 16.3.1.6. Vietnam
      • 16.3.1.7. Rest of South Asia
    • 16.3.2. By Virus Type
    • 16.3.3. By Expression System
    • 16.3.4. By Application
    • 16.3.5. By End User
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Virus Type
    • 16.4.3. By Expression System
    • 16.4.4. By Application
    • 16.4.5. By End User
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Viral Vector Manufacturing Market
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Virus Type
        • 16.8.1.2.2. By Expression System
        • 16.8.1.2.3. By Application
        • 16.8.1.2.4. By End User
    • 16.8.2. Indonesia Viral Vector Manufacturing Market
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Virus Type
        • 16.8.2.2.2. By Expression System
        • 16.8.2.2.3. By Application
        • 16.8.2.2.4. By End User
    • 16.8.3. Malaysia Viral Vector Manufacturing Market
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.3.2.1. By Virus Type
        • 16.8.3.2.2. By Expression System
        • 16.8.3.2.3. By Application
        • 16.8.3.2.4. By End User
    • 16.8.4. Philippines Viral Vector Manufacturing Market
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.4.2.1. By Virus Type
        • 16.8.4.2.2. By Expression System
        • 16.8.4.2.3. By Application
        • 16.8.4.2.4. By End User
    • 16.8.5. Thailand Viral Vector Manufacturing Market
      • 16.8.5.1. Introduction
      • 16.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.5.2.1. By Virus Type
        • 16.8.5.2.2. By Expression System
        • 16.8.5.2.3. By Application
        • 16.8.5.2.4. By End User
    • 16.8.6. Vietnam Viral Vector Manufacturing Market
      • 16.8.6.1. Introduction
      • 16.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.6.2.1. By Virus Type
        • 16.8.6.2.2. By Expression System
        • 16.8.6.2.3. By Application
        • 16.8.6.2.4. By End User

17. East Asia Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 17.3.1. By Country
      • 17.3.1.1. China
      • 17.3.1.2. Japan
      • 17.3.1.3. South Korea
    • 17.3.2. By Virus Type
    • 17.3.3. By Expression System
    • 17.3.4. By Application
    • 17.3.5. By End User
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Virus Type
    • 17.4.3. By Expression System
    • 17.4.4. By Application
    • 17.4.5. By End User
  • 17.5. Market Trends
  • 17.6. Key Market Participants - Intensity Mapping
  • 17.7. Drivers and Restraints - Impact Analysis
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. China Viral Vector Manufacturing Market
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Virus Type
        • 17.8.1.2.2. By Expression System
        • 17.8.1.2.3. By Application
        • 17.8.1.2.4. By End User
    • 17.8.2. Japan Viral Vector Manufacturing Market
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Virus Type
        • 17.8.2.2.2. By Expression System
        • 17.8.2.2.3. By Application
        • 17.8.2.2.4. By End User
    • 17.8.3. South Korea Viral Vector Manufacturing Market
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Virus Type
        • 17.8.3.2.2. By Expression System
        • 17.8.3.2.3. By Application
        • 17.8.3.2.4. By End User

18. Oceania Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 18.3.1. By Country
      • 18.3.1.1. Australia
      • 18.3.1.2. New Zealand
    • 18.3.2. By Virus Type
    • 18.3.3. By Expression System
    • 18.3.4. By Application
    • 18.3.5. By End User
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Virus Type
    • 18.4.3. By Expression System
    • 18.4.4. By Application
    • 18.4.5. By End User
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. Australia Viral Vector Manufacturing Market
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.1.2.1. By Virus Type
        • 18.8.1.2.2. By Expression System
        • 18.8.1.2.3. By Application
        • 18.8.1.2.4. By End User
    • 18.8.2. New Zealand Viral Vector Manufacturing Market
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 18.8.2.2.1. By Virus Type
        • 18.8.2.2.2. By Expression System
        • 18.8.2.2.3. By Application
        • 18.8.2.2.4. By End User

19. Middle East and Africa Viral Vector Manufacturing Market Analysis 2019-2023 and Forecast 2024-2032

  • 19.1. Introduction
  • 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
  • 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Market Taxonomy, 2024-2032
    • 19.3.1. By Country
      • 19.3.1.1. GCC Countries
      • 19.3.1.2. Turkey
      • 19.3.1.3. Israel
      • 19.3.1.4. Northern Africa
      • 19.3.1.5. South Africa
      • 19.3.1.6. Rest of Middle East and Africa
    • 19.3.2. By Virus Type
    • 19.3.3. By Expression System
    • 19.3.4. By Application
    • 19.3.5. By End User
  • 19.4. Market Attractiveness Analysis
    • 19.4.1. By Country
    • 19.4.2. By Virus Type
    • 19.4.3. By Expression System
    • 19.4.4. By Application
    • 19.4.5. By End User
  • 19.5. Market Trends
  • 19.6. Key Market Participants - Intensity Mapping
  • 19.7. Drivers and Restraints - Impact Analysis
  • 19.8. Country Level Analysis & Forecast
    • 19.8.1. GCC Countries Viral Vector Manufacturing Market
      • 19.8.1.1. Introduction
      • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.1.2.1. By Virus Type
        • 19.8.1.2.2. By Expression System
        • 19.8.1.2.3. By Application
        • 19.8.1.2.4. By End User
    • 19.8.2. Turkey Viral Vector Manufacturing Market
      • 19.8.2.1. Introduction
      • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.2.2.1. By Virus Type
        • 19.8.2.2.2. By Expression System
        • 19.8.2.2.3. By Application
        • 19.8.2.2.4. By End User
    • 19.8.3. Israel Viral Vector Manufacturing Market
      • 19.8.3.1. Introduction
      • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.3.2.1. By Virus Type
        • 19.8.3.2.2. By Expression System
        • 19.8.3.2.3. By Application
        • 19.8.3.2.4. By End User
    • 19.8.4. South Africa Viral Vector Manufacturing Market
      • 19.8.4.1. Introduction
      • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.4.2.1. By Virus Type
        • 19.8.4.2.2. By Expression System
        • 19.8.4.2.3. By Application
        • 19.8.4.2.4. By End User
    • 19.8.5. North Africa Viral Vector Manufacturing Market
      • 19.8.5.1. Introduction
      • 19.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 19.8.5.2.1. By Virus Type
        • 19.8.5.2.2. By Expression System
        • 19.8.5.2.3. By Application
        • 19.8.5.2.4. By End User

20. Market Structure Analysis

  • 20.1. Market Analysis by Tier of Companies
  • 20.2. Market Share Analysis of Top Players
  • 20.3. Market Presence Analysis
    • 20.3.1. Regional Footprint of Players
    • 20.3.2. Product Foot Print by Players
    • 20.3.3. Channel Foot Print by Players

21. Competition Analysis

  • 21.1. Competition Dashboard
  • 21.2. Competition Benchmarking
  • 21.3. Competition Deep Dive
    • 21.3.1. Thermo Fisher Scientific Inc
      • 21.3.1.1. Overview
      • 21.3.1.2. Product Portfolio
      • 21.3.1.3. Sales Footprint
      • 21.3.1.4. Key Financials
      • 21.3.1.5. SWOT Analysis
      • 21.3.1.6. Strategy Overview
        • 21.3.1.6.1. Marketing Strategy
        • 21.3.1.6.2. Product Strategy
        • 21.3.1.6.3. Channel Strategy
    • 21.3.2. Charles River (Cobra Biologics)
      • 21.3.2.1. Overview
      • 21.3.2.2. Product Portfolio
      • 21.3.2.3. Sales Footprint
      • 21.3.2.4. Key Financials
      • 21.3.2.5. SWOT Analysis
      • 21.3.2.6. Strategy Overview
        • 21.3.2.6.1. Marketing Strategy
        • 21.3.2.6.2. Product Strategy
        • 21.3.2.6.3. Channel Strategy
    • 21.3.3. Novasep
      • 21.3.3.1. Overview
      • 21.3.3.2. Product Portfolio
      • 21.3.3.3. Sales Footprint
      • 21.3.3.4. Key Financials
      • 21.3.3.5. SWOT Analysis
      • 21.3.3.6. Strategy Overview
        • 21.3.3.6.1. Marketing Strategy
        • 21.3.3.6.2. Product Strategy
        • 21.3.3.6.3. Channel Strategy
    • 21.3.4. uniQure N.V.
      • 21.3.4.1. Overview
      • 21.3.4.2. Product Portfolio
      • 21.3.4.3. Sales Footprint
      • 21.3.4.4. Key Financials
      • 21.3.4.5. SWOT Analysis
      • 21.3.4.6. Strategy Overview
        • 21.3.4.6.1. Marketing Strategy
        • 21.3.4.6.2. Product Strategy
        • 21.3.4.6.3. Channel Strategy
    • 21.3.5. Waisman Biomanufacturing
      • 21.3.5.1. Overview
      • 21.3.5.2. Product Portfolio
      • 21.3.5.3. Sales Footprint
      • 21.3.5.4. Key Financials
      • 21.3.5.5. SWOT Analysis
      • 21.3.5.6. Strategy Overview
        • 21.3.5.6.1. Marketing Strategy
        • 21.3.5.6.2. Product Strategy
        • 21.3.5.6.3. Channel Strategy
    • 21.3.6. Creative Biogene
      • 21.3.6.1. Overview
      • 21.3.6.2. Product Portfolio
      • 21.3.6.3. Sales Footprint
      • 21.3.6.4. Key Financials
      • 21.3.6.5. SWOT Analysis
      • 21.3.6.6. Strategy Overview
        • 21.3.6.6.1. Marketing Strategy
        • 21.3.6.6.2. Product Strategy
        • 21.3.6.6.3. Channel Strategy
    • 21.3.7. GenScript Biotech Corporation
      • 21.3.7.1. Overview
      • 21.3.7.2. Product Portfolio
      • 21.3.7.3. Sales Footprint
      • 21.3.7.4. Key Financials
      • 21.3.7.5. SWOT Analysis
      • 21.3.7.6. Strategy Overview
        • 21.3.7.6.1. Marketing Strategy
        • 21.3.7.6.2. Product Strategy
        • 21.3.7.6.3. Channel Strategy
    • 21.3.8. Novartis AG
      • 21.3.8.1. Overview
      • 21.3.8.2. Product Portfolio
      • 21.3.8.3. Sales Footprint
      • 21.3.8.4. Key Financials
      • 21.3.8.5. SWOT Analysis
      • 21.3.8.6. Strategy Overview
        • 21.3.8.6.1. Marketing Strategy
        • 21.3.8.6.2. Product Strategy
        • 21.3.8.6.3. Channel Strategy
    • 21.3.9. Merck KGaA.
      • 21.3.9.1. Overview
      • 21.3.9.2. Product Portfolio
      • 21.3.9.3. Sales Footprint
      • 21.3.9.4. Key Financials
      • 21.3.9.5. SWOT Analysis
      • 21.3.9.6. Strategy Overview
        • 21.3.9.6.1. Marketing Strategy
        • 21.3.9.6.2. Product Strategy
        • 21.3.9.6.3. Channel Strategy
    • 21.3.10. Takara Bio Inc.
      • 21.3.10.1. Overview
      • 21.3.10.2. Product Portfolio
      • 21.3.10.3. Sales Footprint
      • 21.3.10.4. Key Financials
      • 21.3.10.5. SWOT Analysis
      • 21.3.10.6. Strategy Overview
        • 21.3.10.6.1. Marketing Strategy
        • 21.3.10.6.2. Product Strategy
        • 21.3.10.6.3. Channel Strategy
    • 21.3.11. FUJIFILM Diosynth Biotechnologies
      • 21.3.11.1. Overview
      • 21.3.11.2. Product Portfolio
      • 21.3.11.3. Sales Footprint
      • 21.3.11.4. Key Financials
      • 21.3.11.5. SWOT Analysis
      • 21.3.11.6. Strategy Overview
        • 21.3.11.6.1. Marketing Strategy
        • 21.3.11.6.2. Product Strategy
        • 21.3.11.6.3. Channel Strategy
    • 21.3.12. Lonza
      • 21.3.12.1. Overview
      • 21.3.12.2. Product Portfolio
      • 21.3.12.3. Sales Footprint
      • 21.3.12.4. Key Financials
      • 21.3.12.5. SWOT Analysis
      • 21.3.12.6. Strategy Overview
        • 21.3.12.6.1. Marketing Strategy
        • 21.3.12.6.2. Product Strategy
        • 21.3.12.6.3. Channel Strategy
    • 21.3.13. Danaher Corp. (Aldevron)
      • 21.3.13.1. Overview
      • 21.3.13.2. Product Portfolio
      • 21.3.13.3. Sales Footprint
      • 21.3.13.4. Key Financials
      • 21.3.13.5. SWOT Analysis
      • 21.3.13.6. Strategy Overview
        • 21.3.13.6.1. Marketing Strategy
        • 21.3.13.6.2. Product Strategy
        • 21.3.13.6.3. Channel Strategy
    • 21.3.14. Sirion-Biotech GmbH
      • 21.3.14.1. Overview
      • 21.3.14.2. Product Portfolio
      • 21.3.14.3. Sales Footprint
      • 21.3.14.4. Key Financials
      • 21.3.14.5. SWOT Analysis
      • 21.3.14.6. Strategy Overview
        • 21.3.14.6.1. Marketing Strategy
        • 21.3.14.6.2. Product Strategy
        • 21.3.14.6.3. Channel Strategy
    • 21.3.15. AGC Biologics
      • 21.3.15.1. Overview
      • 21.3.15.2. Product Portfolio
      • 21.3.15.3. Sales Footprint
      • 21.3.15.4. Key Financials
      • 21.3.15.5. SWOT Analysis
      • 21.3.15.6. Strategy Overview
        • 21.3.15.6.1. Marketing Strategy
        • 21.3.15.6.2. Product Strategy
        • 21.3.15.6.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology